Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.
“This TWiST (time without symptoms or toxicity) analysis benefit means that patients treated with niraparib experienced more progression-free time without symptoms or toxicities due to nausea, vomiting, or fatigue compared to placebo,” Ursula A. Matulonis, M.D., director and chief of gynecologic oncology at Dana-Farber Cancer Institute, said during her presentation at the 50th SGO Annual Meeting, held March 16-19 in Honolulu, Hawaii.
BY KRISTIE L. KAHL PUBLISHED MARCH 17,2019
In the multicenter, double-blind, randomized-controlled trial, patients with recurrent ovarian cancer who were in response to their last platinum-based chemotherapy were randomly assigned to receive either 300 mg of Zejula once daily as a maintenance treatment – including 138 patients in the germline BRCA-mutated cohort and 234 in the non-germline group – or placebo – made up of 65 patients in the germline BRCA-mutated cohort and 116 in the non-germline group.
https://www.curetoday.com/articles/zejula-maintenance-therapy-extends-survival-with-toxicities-in-recurrent-ovarian-cancer
Zejula Maintenance Therapy Extends Survival With Toxicities in Recurrent Ovarian Cancer
Posted in Research.